-
Biotech/Pharma Stocks Investor News Alert
Wednesday, July 6, 2011 - 10:52am | 1385Point Roberts, WA - July 6, 2011 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for July 5, 2011. The NASDAQ Biotech Stock Index closed at 1,123.61, up 3.05. The AMEX Biotech Index (^BTK) closed up at 1,...
-
Jefferies Raises PT on Elan to $19
Wednesday, July 6, 2011 - 9:18am | 122Jefferies is out with its report today on Elan (NYSE: ELN), raising its PT from $12 to $19. In a note to clients, Jefferies writes, "Now that Elan has almost doubled since we initiated in January, much has changed that we feel warrants an increase in our price target from $12 to $19. Concerns...
-
"Can Stocks Be Safer than Bonds?"
Wednesday, July 6, 2011 - 8:14am | 802Felix Salmon explores this idea in a post and concludes probably not. I would submit that the way the question is posed and addressed are actually framed incorrectly. If we start by proclaiming that bonds are safer than stocks then you'd probably get a lot of shrugs of acceptance. Invoking Karl...
-
Cell Signaling Technology Grants a Patent License to Pfizer
Tuesday, July 5, 2011 - 4:31pm | 162Cell Signaling Technology, Inc. today announced that it has entered into an agreement with Pfizer Inc. (NYSE: PFE) that provides Pfizer with a worldwide non-exclusive license under the patent estates pooled by CST and Astellas Pharma, Inc. relating to EML4 anaplastic lymphoma kinase. The fusion...
-
Puts Purchased on Jazz Pharmaceuticals
Tuesday, July 5, 2011 - 11:34am | 115Shares of Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) are higher on the session by 3.88%, currently trading at $36.15. The stock has been moving largely higher over the past six months and is currently trading above the 50-day moving average. Options traders are buying puts on the name today. A...
-
Calls Purchased on BioMimetic Therapeutics
Tuesday, July 5, 2011 - 10:36am | 109Shares of BioMimetic Therapeutics (NASDAQ: BMTI) are lower on the session by 0.21%, currently trading at $4.69. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options traders are buying calls on the name today. A short...
-
Piper Jaffray Remains Neutral On Johnson & Johnson
Tuesday, July 5, 2011 - 9:27am | 95According to Piper Jaffray, Johnson & Johnson (NYSE: JNJ) Neutral rating is maintained. Piper Jaffray said that, after a long wait, the approval of Xarelto for the prevention of DVT following knee and hip replacement comes as a bit of a relief, two years after an FDA panel recommended approval...
-
UPDATE: Duncan-Williams Color on Salix Pharmaceuticals Upgrade
Tuesday, July 5, 2011 - 8:31am | 102Duncan-Williams, which upgraded shares of Salix Pharmaceuticals (NASDAQ: SLXP), is providing some color on the stock. “We use DCF analysis (11.5% WACC, down from 12.5% previously, and a 1% terminal growth rate) to arrive at our price target,” Duncan-Williams writes. “We believe the IBS situation...
-
Citi Maintains Buy on Endo Pharmaceuticals
Tuesday, July 5, 2011 - 8:29am | 91Citi is out with its report today on Endo Pharmaceuticals (NASDAQ: ENDP), maintaining Buy. In a note to clients, Citi writes, "We rate the shares of Endo as Buy/High Risk (1H). We expect Lidoderm and the Opana/Opana ER franchise to continue to generate material cash flows for several years beyond...
-
Benzinga's Top Pre-Market NASDAQ Losers
Tuesday, July 5, 2011 - 8:17am | 95Allot Communications Ltd (NASDAQ: ALLT) dipped 5.95% to $16.90 in the pre-market session. ALLT's trailing-twelve-month ROE is -5.72%. Huntington Bancshares Incorporated (NASDAQ: HBAN) dropped 0.60% to $6.59 in the pre-market trading. HBAN's PEG ratio is 1.85. Teva Pharmaceutical Industries...
-
Benzinga's Top Upgrades
Tuesday, July 5, 2011 - 8:08am | 143Analysts at Deutsche Bank upgraded SanDisk Corp (NASDAQ: SNDK) from “hold” to “buy.” SanDisk's shares closed at $42.80 on Friday. SanDisk's PEG ratio is 0.63. Analysts at Duncan Williams upgraded Salix Pharmaceuticals Ltd (NASDAQ: SLXP) from “hold” to “buy.” SLXP's shares closed at $39.37 on...
-
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Tuesday, July 5, 2011 - 8:02am | 137Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on June 30, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 342,000 shares of common stock to 73 new employees. Each stock option has an exercise...
-
News Summary for July 5, 2011
Tuesday, July 5, 2011 - 7:59am | 371This is your Benzinga news summary and traders' outlook for Tuesday, July 5, 2011, covering headlines from overnight and Tuesday's pre-market session. Today in domestic pre-market trading, U.S. equity futures and the U.S. dollar are trading slightly higher after a long weekend and following global...
-
Novartis Drug Afinitor® Met Primary Endpoint Of Phase III Study In Women
Tuesday, July 5, 2011 - 7:40am | 148Novartis (NYSE: NVS) announced today that an interim analysis of a pivotal Phase III study showed Afinitor (everolimus) tablets in combination with exemestane significantly extended progression-free survival, or time without tumor growth, when compared to placebo plus exemestane in women with...
-
Piper Jaffray Reiterates Overweight on Medicis Pharmaceutical
Tuesday, July 5, 2011 - 7:16am | 119Piper Jaffray is out with its report today on Medicis Pharmaceutical (NYSE: MRX), reiterating Overweight. In a note to clients, Piper Jaffray writes, "We remain confident in the outlook for Medicis' aesthetics business and flagship product Solodyn following a recent conversation with senior...